Tert-butyl 5-(aminomethyl)pyridin-3-ylcarbamate | 1017793-23-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Tert-butyl 5-(aminomethyl)pyridin-3-ylcarbamate
• 英文别名: tert-butyl N-[5-(aminomethyl)pyridin-3-yl]carbamate
• CAS: 1017793-23-5
• 化学式: C₁₁H₁₇N₃O₂
• 分子量: 223.275
• InChiKey: OTXAUSMKLLZKEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  77.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(tert-butoxycarbonylamino)-4-(dipropylcarbamoyl)-3H-1-benzazepine-8-carboxylic acid 、 Tert-butyl 5-(aminomethyl)pyridin-3-ylcarbamate 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 tert-butyl N-[5-[[[4-(dipropylcarbamoyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3H-1-benzazepine-8-carbonyl]amino]methyl]pyridin-3-yl]carbamate
  参考文献：
  名称：

  [EN] TLR MODULATOR AND USE THEREOF
  [FR] MODULATEUR DE TLR ET SON UTILISATION
  [ZH] TLR调节剂及其用途

  摘要：

  本申请涉及一种TLR调节剂及其用途，具体而言，本申请涉及调节TLR活性的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐。本申请还涉及本申请化合物的制备方法及其应用。

  公开号：

  WO2023109944A1
• 作为产物：
  描述：

  (5-cyanopyridin-3-yl)carbamic acid tert-butyl ester 在 ammonium hydroxide 、 氢气 作用下， 以 甲醇 为溶剂， 生成 Tert-butyl 5-(aminomethyl)pyridin-3-ylcarbamate
  参考文献：
  名称：

  [EN] TLR MODULATOR AND USE THEREOF
  [FR] MODULATEUR DE TLR ET SON UTILISATION
  [ZH] TLR调节剂及其用途

  摘要：

  本申请涉及一种TLR调节剂及其用途，具体而言，本申请涉及调节TLR活性的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐。本申请还涉及本申请化合物的制备方法及其应用。

  公开号：

  WO2023109944A1

文献信息

• Pyrazolo[1,5-A][1,3,5]triazine and pyrazolo[1,5-A]pyrimidine derivatives as CDK inhibitors
  申请人：Aurigene Discovery Technologies Limited

  公开号：US11186576B2

  公开（公告）日：2021-11-30

  The present invention provides substituted pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives of formula (I), which are therapeutically useful, particularly as selective transcriptional CDK inhibitors including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional CDK7 inhibitors wherein X, ring A, ring B, L1, L2, R1, R2, R3, R4, R6, m, n and p have the meanings given in the specification and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder associated with selective transcriptional CDKs in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives of formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

  本发明提供了取代的式(I)吡唑并[1,5-a][1,3,5]三嗪和吡唑并[1,5-a]嘧啶衍生物，它们具有治疗作用，特别是作为选择性转录 CDK 抑制剂，包括 CDK7、CDK9、CDK12、CDK13 和 CDK18，尤其是转录 CDK7 抑制剂 其中X、环A、环B、L1、L2、R1、R2、R3、R4、R6、m、n和p具有说明书中给出的含义，以及其药学上可接受的盐，可用于治疗和预防哺乳动物中与选择性转录CDK相关的疾病或紊乱。本发明还提供了包含至少一种式（I）的取代吡唑并[1,5-a][1,3,5]三嗪和吡唑并[1,5-a]嘧啶衍生物或其药学上可接受的盐或其立体异构体的化合物和药物制剂的制备方法。
• Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors
  申请人：Aurigene Discovery Technologies Limited

  公开号：US20180057497A1

  公开（公告）日：2018-03-01

  The present invention provides substituted pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives of formula (I), which are therapeutically useful, particularly as selective transcriptional CDK inhibitors including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional CDK7 inhibitors wherein X, ring A, ring B, L 1 , L 2 , R 1 , R 2 , R 3 , R 4 , R 6 , m, n and p have the meanings given in the specification and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder associated with selective transcriptional CDKs in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives of formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.
• [EN] PYRAZOLO[1,5-A][1,3,5]TRIAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS CDK INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLO[1,5-A][1,3,5]TRIAZINE ET DE PYRAZOLO[1,5-A]PYRIMIDINE UTILISÉS EN TANT QU'INHIBITEURS DE CDK
  申请人：AURIGENE DISCOVERY TECH LTD

  公开号：WO2016142855A2

  公开（公告）日：2016-09-15

  The present invention provides substituted pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives of formula (I), which are therapeutically useful, particularly as selective transcriptional CDK inhibitors including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional CDK7 inhibitors wherein X, ring A, ring B, L1, L2, R1,R2, R3, R4, R6, m, n and p have the meanings given in the specification and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder associated with selective transcriptional CDKs in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives of formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.